Seawolf-class submarines combine formidable power with exceptional stealth. Seawolf Therapeutics’ DNA-based therapies are, likewise, built to be both potent and exceptionally immune quiet. To achieve this, we have developed the TRIDENT™ (Targeted RNA-Induced DNA Expression via Nuclear Translocation) system.
DNA delivery, done better
DNA LNPs, powered by TRIDENTTM
TRIDENT consists of:
- An immune quiet DNA payload encoding a therapeutic protein of interest
- A proprietary mRNA payload encoding an auxiliary factor that facilitates DNA access to the nucleus
- A proprietary, targetable lipid nanoparticle (LNP) formulation built to deliver DNA and RNA
TRIDENT achieves therapeutically relevant levels of protein in non-human primates and rodents with minimal signs of immune activation or liver toxicity. TRIDENT-mediated expression is durable and drives meaningful disease modification in animal models of metabolic and rare diseases.
Redefining Nucleic Acid Therapeutics
Seawolf’s TRIDENT system expands the therapeutic toolkit and enables a new treatment paradigm for patients living with serious diseases. TRIDENT marries the potency, redosability, safety and scalability of short-lived RNA-based LNP therapies with the durability of DNA, resulting in a new class of LNP medicines that offers a scalable solution for continuous protein therapy and gene supplementation.
Our first applications include addressing metabolic diseases by expressing biologics from hepatocytes, with research efforts underway to extend the technology’s reach to organs and cellular targets beyond the liver.
Partner With Us
Explore how TRIDENT can power your pipeline. The TRIDENT system is cell agnostic and designed for versatility across a wide range of therapeutic applications. For partnership, licensing, or collaboration inquiries, please contact us at BD@seawolftx.com.
